Clearmind Medicine (CMND) Liabilities and Shareholders Equity (2021 - 2026)
Clearmind Medicine (CMND) posted quarterly Liabilities and Shareholders Equity of $14.5 million for Q2 2026, up 180.35% year-over-year from $5.2 million in Q2 2025, and up 30.33% quarter-over-quarter from $11.1 million in Q1 2026.
Clearmind Medicine (CMND) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Clearmind Medicine's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $14.5 million for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity rose 180.35% year-over-year to $14.5 million; the TTM figure through Apr 2026 stood at $35.7 million (up 31.35% YoY), while the FY2025 annual figure was $6.1 million, down 16.16% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $14.5 million, up from $11.1 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $14.5 million in Q2 2026, with the low at $849246.5 in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $6.3 million (2025), against an average of $7.0 million.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity slumped 79.31% in 2022, then surged 601.01% in 2023.
- Clearmind Medicine's Liabilities and Shareholders Equity stood at $849246.5 in 2022, then surged by 601.01% to $6.0 million in 2023, then grew by 21.87% to $7.3 million in 2024, then dropped by 16.16% to $6.1 million in 2025, then surged by 138.75% to $14.5 million in 2026.
- Business Quant data shows CMND's Liabilities and Shareholders Equity at $14.5 million in Q2 2026, $11.1 million in Q1 2026, and $6.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - | 14.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 14.52 Mn |
| Jan 31, 2026 | 11.14 Mn |
| Oct 31, 2025 | 6.08 Mn |
| Jul 31, 2025 | 3.97 Mn |
| Apr 30, 2025 | 5.18 Mn |
| Jan 31, 2025 | 6.58 Mn |
| Oct 31, 2024 | 7.26 Mn |
| Jul 31, 2024 | 8.17 Mn |
| Apr 30, 2024 | 8.85 Mn |
| Jan 31, 2024 | 10.10 Mn |
| Oct 31, 2023 | 5.95 Mn |
| Jul 31, 2023 | 4.49 Mn |
| Jan 31, 2023 | 4.61 Mn |
| Oct 31, 2022 | 849,246.47 |
| Oct 31, 2021 | 4.10 Mn |